Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-BRAVE: nivolumab-AVD versus BrECADD in advanced Hodgkin lymphoma
2026-525263-41-00Phase 3Authorised
- Sponsor
- Polish Lymphoma Research Group
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab and brentuximab vedotin in Hodgkin lymphoma (HL) (2 arms), sponsored by Polish Lymphoma Research Group. Primary endpoint: Complete metabolic response rate. Planned start Aug 2026; status: authorised.
02
Drugs
nivolumabbrentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2026-525263-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525263-41-00.